The ring was deemed safe and acceptable in adolescents, and, the results were favorable: adherence to the ring was high— “drug levels in 87% of blood samples and 95% of used rings met prespecified adherence criteria.” Furthermore, a whopping 93% of participants reported to like the ring; the common concerns involved keeping the ring clean and worry that their sexual partners might feel it during sexual intercourse.
“We are encouraged by these results of the dapivirine ring in 15- to 17-year olds,” Sharon Hillier, PhD, principal investigator of the NIH-funded Microbicide Trials Network (MTN), said in the press release. “The study has demonstrated that the ring is safe in US teens, and now we need data on the safety and acceptability of the ring in African adolescent girls. The REACH study, scheduled to launch later this year, will generate this data.”
For the REACH study, the investigators aim to gage the safety and efficacy of the dapivirine ring and the use of oral Truvada
as pre-exposure prophylaxis among African adolescent girls and young women between the ages of 16 and 21. In addition, the researchers will evaluate how participants use the 2 preventive methods and what their preferences are for both approaches.
Feature Picture Source: National Institutes of Health
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.